Vaccine: FluMist
Company: MedImmune
Approval Date: June 20
Protects Against: Influenza

MedImmune, maker of the nasal spray influenza vaccine FluMist, entered the 2012-2013 flu season well-prepared; the company says it has 620,000 extra doses on hand during a time when flu vaccines are in demand and running low. Approved for individuals ages 2 to 49, the vaccine first entered the market in 2003. The spray vaccine differs from its needle-delivered counterparts in that it allows patients to avoid a painful or uncomfortable shot. In 2012, FluMist sales hit an estimated $162 million.

In May 2012, MedImmune teamed with Hemispherx Biopharma ($HEB) to test that company's RNA-based adjuvant, Ampligen, intranasally in combination with FluMist. Preclinical research conducted in Japan showed that Ampligen could amplify immune response to influenza vaccines.

For more:
Special Report: Top 10 selling flu vaccines of 2012
Ampligen-FluMist nasal trial begins
Vaccine maker MedImmune has a new AZ chief
AstraZeneca's FluMist Quadrivalent to hit U.S. market


Suggested Articles

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.

Merck just last month won the world's first licensure for an Ebola vaccine. Now, an international group authorized funding to establish a stockpile.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.